{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:31:17Z","timestamp":1781508677171,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,3,12]],"date-time":"2010-03-12T00:00:00Z","timestamp":1268352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Background:<\/jats:italic>\n                    Systemic isotretinoin has been known for decades to be effective in the treatment of severe forms of rosacea, but it must be used off\u2010label because of the lack of evidence\u2010based data.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Patients and Methods:<\/jats:italic>\n                    573 patients with rosacea subtype II and III received one of three different dosages of isotretinoin (0.1 mg, 0.3 mg, or 0.5 mg per kg body weight), doxycycline (100 mg daily for 14 days, then 50 mg daily) or placebo in a double\u2010blinded, randomized way for 12 weeks in 35 German centers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results:<\/jats:italic>\n                    Isotretinoin 0.3 mg\/kg proved to be the most effective dose with significant superiority versus placebo. Isotretinoin 0.3 mg\/kg showed also significant non\u2010inferiority versus doxycycline with reduction of lesions of 90 % compared to 83 % with doxycycline. Investigators diagnosed complete remission in 24 % and marked improvement in further 57 % of patients with isotretinoin treatment, in contrast to remission in 14 % and marked improvement in 55 % of patients treated with doxycycline. Isotretinoin 0.3 mg\/kg revealed a similar safety profile as for the treatment of acne. Isotretinoin 0.5 mg\/kg showed more dermatitis facialis as compared to 0.3 mg\/kg.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions:<\/jats:italic>\n                    Isotretinoin 0.3 mg\/kg is an effective and well\u2010tolerated therapy option for the treatment of rosacea subtype II and III and can therefore be used successfully as an alternative to therapy with oral antibiotics.\n                  <\/jats:p>","DOI":"10.1111\/j.1610-0387.2010.07345.x","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T08:56:42Z","timestamp":1284713802000},"page":"505-514","source":"Crossref","is-referenced-by-count":19,"title":["Systemic isotretinoin in the treatment of rosacea \u2013 doxycycline\u2010 and placebo\u2010controlled, randomized clinical study"],"prefix":"10.1111","volume":"8","author":[{"given":"Harald","family":"Gollnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Blume\u2010Peytavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E\u00f6rs L\u0101szl\u014d","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl\u2010Gustav","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zwingers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Willers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Von Der Weth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,24]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197902153000701"},{"key":"e_1_2_7_3_2","first-page":"575","article-title":"Behandlung der Rosacea mit 13\u2010cis\u2010Retins\u00e4ure","volume":"32","author":"Nikolowski J","year":"1981","journal-title":"Hautarzt"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(82)70067-2"},{"key":"e_1_2_7_5_2","first-page":"173","article-title":"In\u2010vivo\u2010Test zum Nachweis der antiinflammatorischen Wirkung der 13\u2010cis\u2010Retins\u00e4ure","volume":"168","author":"Nikolowski J","year":"1982","journal-title":"Dermatol Monatsschr"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04533.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.084"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_7_9_2","unstructured":"ICH Harmonized Tripartite Guideline: Statistical Principles for Clinica Trials E9. CPMP\/ICH\/363\/96.1998."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2009.04.007"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616"},{"key":"e_1_2_7_13_2","first-page":"5","article-title":"Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists","volume":"82","author":"Del Rosso JQ","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_7_14_2","first-page":"9","article-title":"Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance","volume":"79","author":"Leyden JJ","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_7_15_2","volume-title":"Dermatologische Qualit\u00e4tssicherung. 6. Auflage","author":"Korting HC","year":"2009"},{"key":"e_1_2_7_16_2","first-page":"531","article-title":"American acne & rosacea society rosacea medical management guidelines","volume":"6","author":"Del Rosso JQ","year":"2008","journal-title":"J Drugs Dermatol."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2010.07345.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2010.07345.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:55:31Z","timestamp":1697410531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2010.07345.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,24]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1610-0387.2010.07345.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07345.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4649956.4530054","asserted-by":"object"}]},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,24]]}}}